Levodopa
- Generic Name
- Levodopa
- Brand Names
- Dhivy, Duodopa, Duopa, Inbrija, Parcopa, Prolopa, Rytary, Sinemet, Stalevo
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO4
- CAS Number
- 59-92-7
- Unique Ingredient Identifier
- 46627O600J
- Background
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the b...
- Indication
Levodopa on its own is formulated as an oral inhalation powder indicated for intermittent treatment of off episodes in Parkinson's patients who are already being treated with carbidopa and levodopa. Levodopa is most commonly formulated as an oral tablet with a peripheral dopa decarboxylase inhibitor indicated for treatment of Parkinson's disease, post-enceph...
- Associated Conditions
- Paralysis agitans, Parkinson's Disease (PD), Parkinsonism, Parkinsonism post encephalitic, Restless Legs Syndrome (RLS), Advanced Motor fluctuations
- Associated Therapies
- -
L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- University of Toronto
- Target Recruit Count
- 40
- Registration Number
- NCT02347059
- Locations
- 🇨🇦
Movement disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT02073773
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
- Conditions
- Interventions
- First Posted Date
- 2013-01-17
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 127
- Registration Number
- NCT01770145
- Locations
- 🇺🇸
Henry Ford West Bloomfield Hospital, Bloomfield Hills, Michigan, United States
🇺🇸University of Texas Health Science Center, Houston, Department of Neurology, Houston, Texas, United States
🇺🇸Center for Neurological Care and Research, San Antonio, Texas, United States
Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 346
- Registration Number
- NCT01646255
- Locations
- 🇨🇳
Sp1037 006, Wuhan, China
🇨🇳Sp1037 001, Beijing, China
🇨🇳Sp1037 002, Beijing, China
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
- Conditions
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 600
- Registration Number
- NCT01568073
- Locations
- 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal
Cardiovascular Events in Parkinson's Disease Patients
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01545856
Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 28
- Registration Number
- NCT01504178
- Locations
- 🇫🇷
CIC, Purpan Hospital, Toulouse, France
Use of Zolpidem in Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2011-05-10
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Rush University Medical Center
- Registration Number
- NCT01351168
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
A Trial of Levodopa in Angelman Syndrome
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Wen-Hann Tan
- Target Recruit Count
- 67
- Registration Number
- NCT01281475
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
- Conditions
- Interventions
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 427
- Registration Number
- NCT01227655
- Locations
- 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.